By Mauro Orru 

Roche Holding AG said Friday that data from a pivotal Phase 3 study shows that Alecensa has a higher five-year survival rate than crizotinib for people living with anaplastic lymphoma kinase-positive non-small cell lung cancer.

The Swiss drugmaker said data showed a five-year survival rate of 62.5% with Alecensa, compared with 45.5% for crizotinib.


Write to Mauro Orru at; @MauroOrru94


(END) Dow Jones Newswires

May 29, 2020 01:47 ET (05:47 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.